Equities

Innoviva Inc

Innoviva Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.18
  • Today's Change0.18 / 0.90%
  • Shares traded695.69k
  • 1 Year change+46.66%
  • Beta0.5492
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

  • Revenue in USD (TTM)352.75m
  • Net income in USD64.59m
  • Incorporated1996
  • Employees112.00
  • Location
    Innoviva Inc1350 OLD BAYSHORE HIGHWAY, SUITE 400BURLINGAME 94010United StatesUSA
  • Phone+1 (650) 238-9600
  • Fax+1 (302) 655-5049
  • Websitehttps://www.inva.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avid Bioservices Inc142.36m-144.17m782.13m371.00--13.34--5.49-2.27-2.272.240.91920.36613.814.32383,714.30-37.08-0.826-57.59-1.206.2719.26-101.27-2.141.05-3.180.7343---6.2721.15-54,444.79--84.15--
Eyepoint Pharmaceuticals Inc45.71m-103.57m791.96m121.00--2.85--17.32-2.01-2.010.90184.090.19831.05106.19377,793.40-44.94-40.44-59.48-47.7991.4883.45-226.57-186.235.45--0.00--11.14--30.77------
Pacira Biosciences Inc694.96m-90.73m796.03m711.00--1.06--1.15-2.15-2.1513.0316.240.45481.717.03977,436.00-5.943.35-6.833.9874.3572.63-13.068.571.89--0.43930.001.2214.88163.72--0.8761--
Evolus Inc248.33m-55.46m866.24m322.00--146.91--3.49-0.9141-0.91414.110.09311.254.596.61909,619.10-27.90-40.92-38.48-59.7469.9465.43-22.33-80.462.23-2.040.9537--35.98--17.10--182.77--
Pliant Therapeutics Inc0.00-201.68m912.02m158.00--2.64-----3.34-3.340.005.680.00----0.00-40.90-33.24-43.90-35.39-------360.29----0.0802---83.69---30.83---16.89--
Liquidia Corp14.84m-112.11m926.51m136.00--13.44--62.43-1.57-1.570.21020.82080.0993--4.04109,117.60-75.00-55.02-87.85-62.6969.5282.18-755.46-474.595.78-29.470.578--9.7545.23-91.40--66.93--
Phibro Animal Health Corp1.05bn17.41m966.01m1.94k55.563.7417.980.92290.42930.429325.826.381.082.606.75539,568.101.803.932.204.9031.4731.181.663.771.692.200.647256.454.074.21-92.59-46.356.650.8548
Collegium Pharmaceutical Inc576.65m99.89m1.04bn197.0014.004.804.261.802.302.3012.436.700.50878.143.282,927,173.008.812.7914.584.8061.9450.8817.325.161.043.690.71850.0022.1715.11292.60---54.77--
Phathom Pharmaceuticals Inc9.92m-297.11m1.13bn452.00------114.40-5.13-5.130.1717-3.990.03391.72--21,942.48-101.68-83.26-115.19-93.7780.15---2,995.68-135,982.006.44-5.741.86-------1.96------
Innoviva Inc352.75m64.59m1.26bn112.0029.341.8912.103.580.68790.68794.7810.680.29161.144.443,149,509.005.3426.245.9828.5387.93--18.3176.841.641.930.4011---6.303.53-15.99-14.57----
ANI Pharmaceuticals Inc538.95m22.95m1.29bn642.0051.672.8415.172.401.191.1927.9322.810.60551.813.18839,490.603.04-2.833.56-3.3561.3460.185.01-6.153.073.100.3725--53.8719.28131.250.17549.08--
Tilray Brands Inc812.04m-212.62m1.35bn2.65k--0.375--1.66-0.2746-0.27461.033.970.18752.318.73306,429.10-4.64---5.15--29.42---24.78--1.57-1.160.0953--25.80--83.14------
Avadel Pharmaceuticals PLC (ADR)95.15m-106.22m1.53bn154.00--21.82--16.13-1.17-1.171.040.73060.53080.69415.41617,850.60-59.26-40.21-80.97-47.9994.62---111.64-374.752.52-10.250.00-----22.99-16.59------
Ocular Therapeutix Inc61.10m-138.36m1.73bn267.00--4.57--28.33-1.09-1.090.52492.430.1912.362.12228,827.70-43.26-46.70-47.93-54.1890.8489.36-226.46-228.6516.55-11.300.1509--13.4996.60-13.65--26.37--
Immunocore Holdings PLC - ADR281.45m-53.44m1.74bn497.00--4.83--6.17-1.07-1.075.557.180.35560.56795.56566,303.60-6.75-27.55-8.35-36.8299.41---18.99-97.125.15--0.5495--43.0551.23-5.22--2.85--
Data as of Nov 08 2024. Currency figures normalised to Innoviva Inc's reporting currency: US Dollar USD

Institutional shareholders

76.23%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20248.56m13.69%
Sarissa Capital Management LPas of 30 Jun 20247.28m11.63%
Putnam Investment Management LLCas of 30 Jun 20246.55m10.48%
The Vanguard Group, Inc.as of 30 Jun 20246.07m9.70%
Dimensional Fund Advisors LPas of 30 Sep 20244.50m7.20%
Renaissance Technologies LLCas of 30 Jun 20244.33m6.92%
Pacer Advisors, Inc.as of 30 Jun 20243.36m5.37%
Westfield Capital Management Co. LPas of 30 Jun 20242.68m4.28%
SSgA Funds Management, Inc.as of 30 Jun 20242.47m3.95%
Systematic Financial Management LPas of 30 Jun 20241.89m3.02%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.